Novelix Pharmaceuticals Ltd — Updates, 15-04-2025: Company Update

Novelix Pharmaceuticals has submitted a certificate confirming the completion of the dematerialization process for its securities for the quarter ending 31 March 2025. The company's Registrar and Transfer Agent (R&T Agent) verified and cancelled the mutilated securities and updated the depository records within the required timeline. This efficient handling of shares supports the company's operational integrity and may enhance shareholder confidence. While this announcement indicates strong regulatory compliance, investors may perceive it as a neutral impact on the company’s overall financial health, with no immediate risks or opportunities highlighted.